about
Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008.Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma.Primary cutaneous adenoid cystic carcinoma in the United States: incidence, survival, and associated cancers, 1976 to 2005.Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort studyMelanoma of the skin and lateralityIncidence of potentially human papillomavirus-related neoplasms in the United States, 1978 to 2007.Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma.Evaluating research training outcomes: experience from the cancer prevention fellowship program at the National Cancer Institute.Risk factors for second acute myeloid leukemia/myelodysplastic syndrome among survivors of non-Hodgkin lymphoma.Epidemiology of nonkeratinocytic skin cancers among persons with AIDS in the United States.Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States.Adapting postdoctoral training to interdisciplinary science in the 21st century: the Cancer Prevention Fellowship Program at the National Cancer Institute.Review of Hodgkin's disease and lung cancer following non-Hodgkin's lymphoma in Rhode Island and review of the literature.Comparison of age distribution patterns for different histopathologic types of breast carcinoma.Physicians as citizensPost-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018Platelet adhesion at low shear rate: study of a normal populationInfluence of hormones on platelet intracellular calciumParadoxical influence of estrogenic hormones on platelet-endothelial cell interactionsImages in clinical medicine. Pathologic fracturep53 mutations in leukemia and myelodysplastic syndrome after ovarian cancerAssessment of delayed reporting of mycosis fungoides and Sezary syndrome in the United StatesCutaneous lymphomas reported to the National Cancer Institute's surveillance, epidemiology, and end results program: applying the new WHO-European Organisation for Research and Treatment of Cancer classification systemCause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia, 2000-2016Potential underestimation of cerebrovascular events in the PROVENGE Registry for the observation, collection, and evaluation of experience dataRisk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypesErythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999-2017Case series of reports of pruritus and sipuleucel-T submitted to the Food and Drug Administration Adverse Event Reporting System
P50
Q30538788-EFC6CDA0-EB0A-4B1A-9389-F20D4757E508Q33618971-3781B22F-9964-4AB1-B471-5FD1837F3D57Q33912539-BF7F5105-C89E-44F6-ADA0-8D4073E91F7AQ34173479-8D922FED-583D-41AA-A4D8-3B4A33E5610BQ34447413-E6841C9D-355B-49FF-A4BA-1B6882ECE368Q36053749-8C29979E-2930-47E2-9008-E1E984939998Q36090959-C745D651-27DE-4DE7-A673-0E8C2C190D01Q36489980-051B6D4D-7272-4005-A670-E32C182E61A9Q36689790-9D5E7BD3-D5E8-42DC-B51E-E4E648A6334FQ37309589-287E54B2-4C6E-463B-966C-A058245B9C9EQ37426719-D8FA0336-50BE-45B3-ADEE-80B673FC72E7Q38458796-7E2C75A1-5300-4C2C-9D92-F21CF073806CQ40938689-C5D5216D-36C7-487B-B5E6-F754CA6B2EFAQ51780980-ECCC09F9-CD01-4266-B3C0-EF7C163CA07EQ56902538-891B6C5D-1B2F-49BE-8959-AE0F8EFB460BQ64130547-E80D24CF-B285-407F-BA8B-C92D80C3B45EQ70594327-51A02013-9465-4F24-950B-915C664B1C88Q71930999-88F4F302-3F31-44BE-97A5-1A60EF01BCB0Q72202479-8B32955D-1271-422B-82AF-2B4A0BE7D63EQ73756851-06E39F78-4EB5-4ACE-AA94-92403A9692D7Q74079753-7DC2E95F-0C2A-4E9E-BBC1-A6101C830F21Q80889284-D070A771-DD90-4439-B21C-14AAA2773BB3Q81280316-450F0D6E-C59C-4CAD-886E-510932447F4EQ89850827-C249C476-BFC4-4B71-BF0C-1A43BEC53687Q90185234-2C738772-6DA9-4964-BD6B-47C7F8A0A961Q91525943-B5DD613F-E009-4113-B848-20ABA8D42DDEQ92213839-D3618098-E90E-4FCE-A6F9-0FD30A31A418Q92342295-DCB0EB96-8D12-4C19-9435-599C9BE1205B
P50
description
researcher
@en
name
G M Dores
@en
G M Dores
@nl
type
label
G M Dores
@en
G M Dores
@nl
prefLabel
G M Dores
@en
G M Dores
@nl
P106
P31
P496
0000-0002-3985-2935